Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Pfizer
Roswell Park Cancer Institute
Pfizer
Baylor Research Institute
Institut du Cancer de Montpellier - Val d'Aurelle
Gruppo Oncologico del Nord-Ovest
National Cancer Institute (NCI)
Pfizer
Alliance for Clinical Trials in Oncology
UNICANCER
City of Hope Medical Center
NuCana plc
Institut Bergonié
IFOM ETS - The AIRC Institute of Molecular Oncology
Memorial Sloan Kettering Cancer Center
Pfizer
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
NRG Oncology
Charite University, Berlin, Germany
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
Peking Union Medical College Hospital
Fudan University
Fudan University
Medical University of Vienna
NSABP Foundation Inc
Asan Medical Center
Wake Forest University Health Sciences
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Tanta University
Alliance for Clinical Trials in Oncology
SCRI Development Innovations, LLC
Medical Research Council
Medical Research Council
University of Louisville
China Medical University, China
Fox Chase Cancer Center
UNICANCER
UNICANCER
UNICANCER